Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad announces closing of global offering

Celyad announces closing of global offering

Expression of a TIM peptide reduces alloreactivity of T-cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T-cell therapy approach

Expression of a TIM peptide reduces alloreactivity of T-cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T-cell therapy approach

Celyad announces pricing of $47.3 million global offering

Celyad announces pricing of $47.3 million global offering

Functional screening of an anti-B7H6 specific chimeric antigen receptor (CAR)

Functional screening of an anti-B7H6 specific chimeric antigen receptor (CAR)

Overcoming target-driven fratricide for CAR-T cell therapy

Overcoming target-driven fratricide for CAR-T cell therapy

Celyad announces launch of proposed global offering

Celyad announces launch of proposed global offering

Celyad Announces First Quarter 2018 Business Update

Celyad Announces First Quarter 2018 Business Update

Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018

Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018

Annual report 2017

Annual report 2017

Celyad successfully administers CYAD-01 in first patients in SHRINK and LINK trials

Celyad successfully administers CYAD-01 in first patients in SHRINK and LINK trials

NKG2D-Based Chimeric Antigen Receptor Therapy Induced Remission In A Relapsed/Refractory Acute Myeloid Leukemia Patient.

NKG2D-Based Chimeric Antigen Receptor Therapy Induced Remission In A Relapsed/Refractory Acute Myeloid Leukemia Patient.